Clinical Application of Pharmacogenetics: Where are We Now?

od van Schaik, Ron HN
Izdano u EJIFCC (2014)

6. Dose Adjustments Based on Pharmacogenetics of CYP450 Enzymes

od van Schaik, Ron H.N.
Izdano u EJIFCC (2008)

A Guide to the Current Web-Based Resources in Pharmacogenomics

od Glubb, Dylan M., Paugh, Steven W., van Schaik, Ron H.N., Innocenti, Federico
Izdano 2013

A new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression system

od Lee, Su-Jun, van der Heiden, Ilse P, Goldstein, Joyce A, van Schaik, Ron HN
Izdano 2006

Time of injury affects urinary biomarker predictive values for acute kidney injury in critically ill, non-septic patients

od de Geus, Hilde RH, Fortrie, Gijs, Betjes, Michiel GH, van Schaik, Ron HN, Groeneveld, AB Johan
Izdano 2013

Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside?

od Mura, Elisa, Govoni, Stefano, Racchi, Marco, Carossa, Valeria, Ranzani, Guglielmina Nadia, Allegri, Massimo, van Schaik, Ron HN
Izdano 2013

CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohort

od Dagostino, Concetta, Allegri, Massimo, Napolioni, Valerio, D’Agnelli, Simona, Bignami, Elena, Mutti, Antonio, van Schaik, Ron HN
Izdano u Pharmgenomics Pers Med (2018)

Genetic Variation in the Multidrug and Toxin Extrusion 1 Transporter Protein Influences the Glucose-Lowering Effect of Metformin in Patients With Diabetes: A Preliminary Study

od Becker, Matthijs L., Visser, Loes E., van Schaik, Ron H.N., Hofman, Albert, Uitterlinden, André G., Stricker, Bruno H.Ch.
Izdano 2009

Differences in CYP3A genotypes of a liver transplant recipient and the donor liver graft and adjustment of tacrolimus dose

od Berger, Florine A., Mulder, Midas B., ten Bosch‐Dijksman, Willemijn, van Schaik, Ron H.N., Coenen, Sandra, de Winter, Brenda C.M.
Izdano u Br J Clin Pharmacol (2019)

CYP3A5, ABCB1 and SLCO1B1 Polymorphisms and Pharmacokinetics and Virologic Outcome of Lopinavir/Ritonavir in HIV-infected Children

od Rakhmanina, Natella Y., Neely, Michael, Van Schaik, Ron H.N., Gordish-Dressman, Heather, Williams, Keetra D., Soldin, Steven J., van den Anker, John N.
Izdano 2011

Global pharmacogenomics within precision medicine: challenges and opportunities

od Chenoweth, Meghan J., Giacomini, Kathleen M., Pirmohamed, Munir, Hill, Susan L., van Schaik, Ron H.N., Schwab, Matthias, Shuldiner, Alan R., Relling, Mary V., Tyndale, Rachel F.
Izdano u Clin Pharmacol Ther (2019)

Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites

od Jager, Nynke GL, Koornstra, Rutger HT, Vincent, Andrew D, van Schaik, Ron HN, Huitema, Alwin DR, Korse, Tiny M, Schellens, Jan HM, Linn, Sabine C, Beijnen, Jos H
Izdano 2013

Overweight Kidney Transplant Recipients Are at Risk of Being Overdosed Following Standard Bodyweight-Based Tacrolimus Starting Dose

od Andrews, Louise M., de Winter, Brenda C.M., Tang, Jiang-Tao, Shuker, Nauras, Bouamar, Rachida, van Schaik, Ron H.N., Koch, Birgit C.P., van Gelder, Teun, Hesselink, Dennis A.
Izdano u Transplant Direct (2017)

Minimum information required for a DMET experiment reporting

od Kumuthini, Judit, Mbiyavanga, Mamana, Chimusa, Emile R, Pathak, Jyotishman, Somervuo, Panu, Van Schaik, Ron HN, Dolzan, Vita, Mizzi, Clint, Kalideen, Kusha, Ramesar, Raj S, Macek, Milan, Patrinos, George P, Squassina, Alessio
Izdano u Pharmacogenomics (2016)

Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients

od Francke, Marith I., Hesselink, Dennis A., Li, Yi, Koch, Birgit C.P., de Wit, Lucia E.A., van Schaik, Ron H.N., Yang, Lin, Baan, Carla C., van Gelder, Teun, de Winter, Brenda C.M.
Izdano u Br J Clin Pharmacol (2020)

Influence of Genetic Variation in COMT on Cisplatin-Induced Nephrotoxicity in Cancer Patients

od Agema, Bram C., Koolen, Stijn L.W., de With, Mirjam, van Doorn, Nadia, Heersche, Niels, Oomen-de Hoop, Esther, Visser, Sabine, Aerts, Joachim G.J.V., Bins, Sander, van Schaik, Ron H.N., Mathijssen, Ron H.J.
Izdano u Genes (Basel) (2020)

Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment

od Del Re, Marzia, Bordi, Paola, Petrini, Iacopo, Rofi, Eleonora, Mazzoni, Francesca, Belluomini, Lorenzo, Vasile, Enrico, Restante, Giuliana, Di Costanzo, Francesco, Falcone, Alfredo, Frassoldati, Antonio, van Schaik, Ron H.N., Steendam, Christi M.J., Chella, Antonio, Tiseo, Marcello, Morganti, Riccardo, Danesi, Romano
Izdano u Oncotarget (2017)

A Multi-Center Study of [−2]Pro-Prostate-Specific Antigen (PSA) in Combination with PSA and Free PSA for Prostate Cancer Detection in the 2.0 to 10.0 ng/mL PSA Range

od Catalona, William J., Partin, Alan W., Sanda, Martin G., Wei, John T., Klee, George G., Bangma, Chris H., Slawin, Kevin M., Marks, Leonard S., Loeb, Stacy, Broyles, Dennis L., Shin, Sanghyuk S., Cruz, Amabelle B., Chan, Daniel W., Sokoll, Lori J., Roberts, William L., van Schaik, Ron H.N., Mizrahi, Isaac A.
Izdano 2011

CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity

od de Graan, Anne-Joy M., Elens, Laure, Sprowl, Jason A., Sparreboom, Alex, Friberg, Lena E., van der Holt, Bronno, de Raaf, Pleun J., de Bruijn, Peter, Engels, Frederike K., Eskens, Ferry A.L.M., Wiemer, Erik A.C., Verweij, Jaap, Mathijssen, Ron H.J., van Schaik, Ron H.N.
Izdano 2013

Prospective, Multi-Center Evaluation of the Beckman Coulter Prostate Health Index Using WHO Calibration

od Loeb, Stacy, Sokoll, Lori J., Broyles, Dennis L., Bangma, Chris H., van Schaik, Ron H.N., Klee, George G., Wei, John T., Sanda, Martin G., Partin, Alan W., Slawin, Kevin M., Marks, Leonard S., Mizrahi, Isaac A., Shin, Sanghyuk S., Cruz, Amabelle B., Chan, Daniel W., Roberts, William L., Catalona, William J.
Izdano u J Urol (2012)